Clinical trial
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon…
NCT00217139 · BioWest Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00217139 |
|---|---|
| Title | A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection |
| Official title | A Phase II, Randomized, Active-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With and Without Ribavirin, for 12 Weeks in Patients With Chronic Hepatitis C Infection (Genotype 1) Who Failed to Respond to Pegylated α… |
| Lead sponsor | BioWest Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Celgosivir |
| Enrollment | 60 |
| Start date | Sep 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 29, 2006 |
| Countries | Canada |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: